Increased PMA-induced chemiluminescence from whole blood of patients with bronchial hyperreactivity

S. Nordman, P. Nyberg, L. Linko

Increased PMA-induced chemiluminescence from whole blood of patients with bronchial hyperreactivity. S. Nordman, P. Nyberg, L. Linko. ©ERS Journals Ltd 1994.

ABSTRACT: Blood phagocytes from patients with asthma have an increased capacity to produce reactive oxygen metabolites. We studied whether whole blood chemiluminescence, serum eosinophilic cationic protein (ECP), and serum myeloperoxidase (MPO) were determined from 50 patients referred for a methacholine challenge due to prolonged cough and/or dyspnea. The chemiluminescence results were compared to those from 15 healthy persons.

The hyperreactive patients (n=18) had significantly higher phorbol 12-myristate 13-acetate (PMA)-induced whole blood chemiluminescence values (mean 18.8 mV·min⁻¹; 95% confidence limits (C.L.) 16.3–21.3 mV·min⁻¹) than the normoreactive patients (mean 14.2 mV·min⁻¹; 95% C.L. 13.0–15.5 mV·min⁻¹) and the healthy controls (mean 12.8 mV·min⁻¹; 95% C.L. 11.7–13.9 mV·min⁻¹). There was no significant difference in PMA-induced chemiluminescence between the normoreactive patients and the controls. The hyperreactive patients had higher serum ECP values than the normoreactive patients, but there was no correlation between whole blood chemiluminescence and serum ECP levels or total eosinophil count. There was no significant difference in monocyte reactive oxygen metabolite production or serum MPO values between the normoreactive and the hyperreactive patients.

We suggest that the increased PMA-induced whole blood chemiluminescence in bronchial hyperreactivity is due mainly to an activation of neutrophils, and that the assay might be useful as a systemic inflammatory marker in patients with pulmonary inflammatory processes resulting in bronchial hyperreactivity.

Eur Respir J., 1994, 7, 1425–1430.

Inflammatory processes are important in the pathogenesis of asthma [1, 2]. Histological and cytological studies have shown an accumulation of phagocytes, i.e. eosinophil and neutrophil granulocytes, monocytes and macrophages, in the airway mucosa and alveolar space of asthmatic subjects [3]. These changes are present even at a clinically early stage of the disease [4]. All phagocytes contain an enzyme complex, the NADPH oxidase, which following activation catalyzes the production of the superoxide radical [5]. From superoxide, other reactive oxygen metabolites (ROMs) may be formed [6]. An inappropriate activation of the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, the physiological role of which lies in the defence against microbes [7], may be involved in the pathogenesis of numerous diseases, including bronchial asthma [8].

Several studies have shown that the ROM metabolism of lung phagocytes is activated in asthma [9–14], but there are also reports of an increased ROM production by peripheral blood phagocytes of asthmatic subjects [15–20]. Peripheral blood phagocyte ROM production may, thus, be useful as a systemic inflammatory marker in asthma. Most of the above-mentioned blood phagocyte studies have been performed using cumbersome techniques, involving time-consuming cell isolation procedures, which decreases the potential for clinical use of these methods. However, ROM production by blood phagocytes may also be estimated with whole blood chemiluminescence, a simple and rapid assay which measures mainly neutrophil-derived hypochlorous acid production [21, 22].

The diagnosis of asthma is usually based on a typical history, together with the demonstration of reversible airflow obstruction [23]. When asthma is being considered but the patient has no current signs of reversible airflow obstruction in lung function tests, measurement of bronchial hyperreactivity with methacholine or histamine challenge tests may be useful [24]. The aim of the present study was to evaluate whether an increased ROM production by peripheral blood phagocytes may be detected with whole blood chemiluminescence in patients.
with respiratory symptoms and bronchial hyperreactivity suggesting asthma, but with normal prechallenge spirometry values. For comparison, we also determined the serum eosinophilic cationic protein (ECP) and myeloperoxidase (MPO) levels, which have been suggested as systemic markers of phagocyte-induced inflammation [25, 26].

Materials and methods

Reagents

Phorbol 12-myristate 13-acetate (PMA) and zymosan A yeast were purchased from Sigma, USA. Zymosan was opsonized with normal human serum, as described previously [27]. Luminol (5-amino-2, 3-dihydro-1, 4-phthalazinedione) was obtained from Bio-Orbit, Turku, Finland; phosphate buffered saline (PBS) from Gibco, Paisley, UK; and Ficoll-Paque from Pharmacia, Uppsala, Sweden.

Patients

Fifty consecutive patients referred for a methacholine challenge test due to respiratory symptoms suggesting asthma, but with a normal forced expiratory volume in one second (FEV₁), were included in the study. Fifteen healthy volunteers with no respiratory symptoms formed a control group. Twenty of the patients suffered from prolonged cough and dyspnoea, 22 from prolonged cough only, and 8 from dyspnoea only. All patients were skin tested with 24 common allergens (Soluprick®, Allergologisk laboratorium A/S, Denmark), and atopy was confirmed, with at least one abnormal response, in 13 cases. Nineteen (38%) of the patients had used no medication before the methacholine challenge. Twenty (40%) of the patients had used topical β₂-agonists, 3 (6%) oral antihistamines, 5 (10%) nasal steroids, and 3 (6%) combinations of the above. β₂-agonists were withheld for 12 hours before the bronchial challenge, and oral antihistamines for at least two weeks.

Methacholine challenge

Methacholine challenge was performed with a Spira Elektro 2 dosimeter with controlled tidal breathing (Respiratory Care Center, Hämeenlinna, Finland) [28], using a slight modification of the protocol described by Nieminen et al. [29]. Methacholine was inhaled in five cumulative doses (18, 72, 270, 800, and 2,600 µg). Three minutes after each methacholine dose, the change in FEV₁ from the prechallenge value was measured. The test was interrupted when FEV₁ fell by at least 20% of the prechallenge value, or when the maximum methacholine dose (2,600 µg) was reached. The fall in FEV₁ was plotted against methacholine dose on a log scale, and the provocative dose causing a 20% fall in FEV₁ (PD₂₀FEV₁) was calculated. The patients with a PD₂₀FEV₁ ≤2,600 µg methacholine were considered hyperreactive.

Blood samples

Twenty millilitres of heparinized blood for the chemiluminescence assays and 20 ml of nonheparinized blood for the enzyme assays were obtained by venepuncture from each person participating in the study, within 30 min before the methacholine challenge. Haemoglobin concentration, leucocyte count, and an automatic differential count were determined with an S-Plus JR Counter Coulter (Coulter Electronics Ltd, Luton, UK). The eosinophil count was determined manually using May-Grünwald-Giemsa (MGG)-stained specimens for the first 28 participants of the study.

Whole blood chemiluminescence

Whole blood chemiluminescence was determined within 15 min after venepuncture. The reaction suspensions contained 100 µl of heparinized blood, 100 µl luminol (5.6×10⁻³ M), 100 µl PMA (1 µg·ml⁻¹), or 150 µl opsonized zymosan (1 mg·ml⁻¹), and phosphate buffered saline (PBS) ad 1 ml. The reactions were started by adding PMA or opsonized zymosan, and the resulting light emission was recorded for 20 min at 2 min intervals with a micro-computer-controlled luminometer (Bio-Orbit, Turku, Finland). The reactions were performed at 37°C, and all measurements were performed in duplicate. The results are expressed as areas under the light emission curves (mV·min⁻¹). The intra-assay reproducibility of the results was determined on five separate occasions with six parallel samples: the coefficient of variation (CV%) of the parallel samples was 5.3±2.0% (mean value±SD).

Isolation of mononuclear leucocytes

Mononuclear cells (monocytes and lymphocytes) were isolated from the first 35 patients included in the study (21 normoreactive and 14 hyperreactive). Ten millilitres of heparinized blood was centrifuged on Ficoll-Paque at 450×g for 30 min, after which the cells were washed twice in PBS at 450×g for 10 min. The cells were counted and the cell number was adjusted to 10×10⁶ cells·ml⁻¹. The monocyte content was determined using MGG-stained cyt centrifuge preparations.

Mononuclear leucocyte chemiluminescence

Fifty microlitres of the mononuclear cell suspension was incubated in luminol at 37°C for 10 min. After incubation, the chemiluminescence assay was performed as described above. The results are expressed as areas under the light emission curves (mV·min⁻¹)·10⁻⁵ monocytes.
ECP and MPO assays

Serum ECP and MPO were determined using commercially available double antibody radio-immunoassays (Pharmacia, Uppsala, Sweden). The ECP assay has been described in detail by Peterson et al. [30], and the MPO assay is based on the method described by Olsson et al. [31]. The results from the enzyme assays were compared to values obtained from 17 healthy volunteers.

Statistics

In the statistical calculations, nonparametric tests (Mann-Whitney’s two-sample, non-matched test, Fisher’s exact four-field test, and Spearman’s correlation test) were used.

Results

The characteristics of the patients and the healthy controls are shown in table 1. Eighteen of the 50 patients with respiratory symptoms had an abnormal methacholine challenge test. There were no statistically significant differences in age, smoking habits, total granulocyte count, or haemoglobin concentration between the three groups. Neither were there any statistically significant differences in the use of antiasthma drugs prior to the challenge test between the hyperreactive and the normoreactive patients, as evaluated with Fisher’s test (data not shown). The proportion of atopics/nonatopics was significantly higher in the hyperreactive group (10 out of 18) than in the normoreactive group (3 out of 32; p<0.001, Fisher’s test).

Figure 1a shows that the hyperreactive patients had a significantly higher PMA-stimulated whole blood CL mean value (18.8 mV·min⁻¹; 95% confidence limits (C.L.) 16.3–21.3mV·min⁻¹) than the normoreactive patients (14.2 mV·min⁻¹; 95% C.L. 13.0–15.5 mV·min⁻¹; p<0.005) and the healthy controls (12.8 mV·min⁻¹; 95% C.L. 11.7–13.9; p<0.0005). There was no statistically significant difference between the normoreactive patients and the healthy controls, or between the hyperreactive patients with atopy (mean 17.7 mV·min⁻¹; 95% C.L. 14.8–20.5 mV·min⁻¹) and those without atopy (mean 20.2 mV·min⁻¹; 95% C.L. 15.1–25.4 mV·min⁻¹). Using the mean value±2 SD from the healthy group as the cut-off level, the test had a sensitivity of 56% and a specificity of 84% for hyperreactivity versus normoreactivity. There was no correlation between the PMA-stimulated whole blood CL values and the methacholine PD₂₀FEV₁ values in the hyperreactive group (Spearman’s correlation coefficient=0.13).

No statistically significant difference was noted between the zymosan-induced whole blood chemiluminescence values of the hyperreactive and the normoreactive patients (fig. 1b), but both groups had significantly higher values than the healthy controls (p<0.05). There were no significant differences in monocyte ROM production between the hyperreactive and normoreactive group, either when PMA or when opsonized zymosan was used as stimulant (data not shown). No close correlation between the total granulocyte count and PMA-induced whole blood chemiluminescence was observed (Spearman’s correlation coefficient=0.34).

Table 1. – Characteristics of the patients and the healthy controls

<table>
<thead>
<tr>
<th></th>
<th>Normoreactive</th>
<th>Hyperreactive</th>
<th>Healthy</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>32</td>
<td>18</td>
<td>15</td>
</tr>
<tr>
<td>Smokers n</td>
<td>2</td>
<td>4†</td>
<td>4</td>
</tr>
<tr>
<td>Age yrs</td>
<td>45±18</td>
<td>40±14*</td>
<td>40±10</td>
</tr>
<tr>
<td>Granulocytes x10⁶</td>
<td>4.0±1.5</td>
<td>4.6±1.7</td>
<td>4.0±1.4</td>
</tr>
<tr>
<td>×10⁶ cells⁻¹</td>
<td>(3.4–4.5)</td>
<td>(3.8–5.5)</td>
<td>(3.2–4.8)</td>
</tr>
<tr>
<td>Haemoglobin g·l⁻¹</td>
<td>138±10</td>
<td>142±13†</td>
<td>134±8</td>
</tr>
<tr>
<td></td>
<td>(135–142)</td>
<td>(135–148)</td>
<td>(130–139)</td>
</tr>
</tbody>
</table>

Values are mean±sd with 95% confidence limits in brackets.
†: nonsignificant (Mann-Whitney); *: nonsignificant (Fisher’s test) compared to both normoreactive and healthy.
The hyperreactive patients had higher serum ECP values (mean 24.4 µg·l⁻¹; 95% C.L. 11.7–36.8 µg·l⁻¹) than the normoreactive patients (mean 10.2 µg·l⁻¹; 95% C.L. 7.9–12.5 µg·l⁻¹; p<0.05) and 17 healthy controls (mean 8.5 µg·l⁻¹; 95% C.L. 6.0–10.9 µg·l⁻¹) (fig. 2a). Using the mean value±2 SD from the controls as the cut-off level, the test had a sensitivity of 39% and a specificity of 84% for hyperreactivity versus normoreactivity. There was no correlation between the PMA-induced whole blood chemiluminescence values and the serum ECP values (Spearman’s correlation coefficient=0.12).

Discussion

The results of this study show higher PMA-induced chemiluminescence values from whole blood of patients with bronchial hyperreactivity than of normoreactive patients and healthy controls. Higher serum ECP values were also noted in the hyperreactive group than in the normoreactive group, whilst serum MPO was equally elevated in both patient groups.

As mentioned above, increased capacity to ROM production by isolated peripheral blood neutrophils of patients with asthma has been reported previously by several groups. A correlation between neutrophil ROM production and bronchial hyperreactivity has been shown both in bronchial asthma [17, 19], and in chronic obstructive pulmonary disease [32]. The magnitude of the neutrophil ROM responses has been reported to correlate with the severity of asthma symptoms [19]. The chemiluminescence signal obtained from whole blood is predominantly a function of neutrophil number and function [33], whilst the contribution of monocytes, lymphocytes and thrombocytes has been considered negligible [22, 34–37]. We observed no close correlation between total granulocyte count and the PMA-induced whole blood chemiluminescence values, which suggests that the chemiluminescence responses were not merely a function of neutrophil number, but also of neutrophil metabolic activity.

We could not observe any significant difference in chemiluminescence responses from the mononuclear cell suspensions of the hyperreactive and normoreactive patients, which suggests that the higher PMA-induced whole blood chemiluminescence values were not due to an activation of monocytes in the hyperreactive group. However, an increased ROM production by monocytes both in asthma [20, 38], and in atopy [39] has been reported. Eosinophils from peripheral blood of asthmatic patients also generate increased amounts of ROMs [18], and these cells might also have contributed to our chemiluminescence results. Several studies have reported elevated serum ECP levels in asthmatic patients, suggesting an activation of eosinophils in asthma (reviewed recently by Venge [25]). In agreement with these studies, we also observed increased ECP values in the hyperreactive group, but there was no correlation between PMA-induced whole blood chemiluminescence and serum ECP levels or eosinophil count, respectively. Also, the chemiluminescence values were not higher in the atopic hyperreactive patients than in the nonatopic subjects, which speaks against a central role for eosinophil-derived ROMs in PMA-induced whole blood chemiluminescence.

Thus, we suggest that the increased PMA-induced whole blood chemiluminescence responses were due mainly to ROMs produced by metabolically activated neutrophils. The elevated serum MPO values in the hyperreactive group also suggest an activation of neutrophil ROM production, but the MPO levels in the normoreactive group were equally increased. Possibly
a common reason for the prolonged cough and/or dyspnoea in the normoreactive group was a subacute bacterial infection, which may explain the increase in serum MPO in this group. Earlier reports concerning serum MPO as an inflammatory marker in asthma have been negative [40, 41].

Only whole blood chemiluminescence induced by PMA was increased in the hyperreactive group. In a recently published study by Nielsen et al. [42], whole blood chemiluminescence responses to the bacterial peptide formyl-methionyl-leucyl-phenylalanine (FMLP) were higher in a group of hyperreactive patients, whilst there were no differences in the responses to the calcium ionophore A23187. Thus, the activation of the phagocytes responsible for the increased whole blood chemiluminescence seems to be selective for certain NADPH oxidase stimulants. The biochemical mechanisms for this finding remain to be explained.

Whole blood chemiluminescence is affected by haemoglobin concentration and serum factors [22, 35, 43, 44]. In our study, the variation in haemoglobin concentration between the patient groups was small; thus, we did not find it necessary to correct the chemiluminescence values for haemoglobin. A correction according to the study by Ristola and Repo [22] did not change the results significantly. Serum in physiological concentrations has an inhibitory effect on luminol-dependent chemiluminescence [44], which may be due, in part, to the presence of antioxidants in serum. Several investigators have shown that asthmatics have lower antioxidant levels in serum [45, 46]. Thus, the higher whole blood chemiluminescence responses in the hyperreactive group might also have been due, in part, to decreased antioxidant levels in serum. However, this effect would probably also have been observed when opsonized zymosan was used as stimulant, which was not the fact.

In conclusion, our results suggest that PMA-induced whole blood chemiluminescence might be useful in detecting a systemic effect of pulmonary inflammatory processes resulting in bronchial hyperreactivity. In our study, the test had a higher sensitivity for bronchial hyperreactivity than serum ECP determination, which has recently been suggested as an inflammatory marker in asthma [25], and as good a specificity. Work is in progress to evaluate whole blood chemiluminescence as an inflammatory marker in the longitudinal follow-up of individual patients with verified asthma during treatment.

Acknowledgements: The authors thank H. Riska, M. Klockars and O. Selroos for their advice and support.

References


